<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804956</url>
  </required_header>
  <id_info>
    <org_study_id>2012.028</org_study_id>
    <nct_id>NCT04804956</nct_id>
  </id_info>
  <brief_title>Mesorectal Microbiome as a Prognostic Factor in Patients With Rectal Cancer</brief_title>
  <acronym>BIORECTUM</acronym>
  <official_title>Mesorectal Microbiome as a Prognostic Factor in Patients With Rectal Cancer and Analysis of it's Applicability in Neoadjuvant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Girona Dr.Josep Trueta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Girona Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of Girona Dr.Josep Trueta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The equilibrium of intestinal microorganisms is essential for health an imbalance has been&#xD;
      associated with an increased risk in the development of different pathologies; including&#xD;
      colorectal cancer.&#xD;
&#xD;
      Rectal cancer is the third most common neoplasm worldwide and the complete excision of the&#xD;
      mesorectum is a major prognostic factor.&#xD;
&#xD;
      The identification of microorganisms in the adipose tissue that surrounds the small intestine&#xD;
      in inflammatory diseases, together with bacterial alterations found in colonic mucosa and&#xD;
      feces in patients with rectal cancer in comparison with healthy individuals indicates that&#xD;
      microbiome alteration plays an essential role in pathogenesis.&#xD;
&#xD;
      The mesorectal microbiome in rectal cancer patients stills unknown and given its importance&#xD;
      in the prognostic of the disease the goal of this study is to identify microbial profiles&#xD;
      that allow predicting rectal cancer patients with a poor prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 5-year survival rate for patients with rectal cancer is 64%. Despite the development of&#xD;
      personalized cancer treatments, the implantation of surgical approaches with more precise&#xD;
      fields of vision and the current prognostic factors based on the quality of resection of the&#xD;
      surgical specimen (intact margins and complete resection of the mesorectum), the long-term&#xD;
      results for patients with rectal cancer remain grim.&#xD;
&#xD;
      Recently, it has been shown that dysfunctional fat tissue is characterized by tissue&#xD;
      remodeling, grater lipids deposits and high adipokines secretion generates a pro inflammatory&#xD;
      state, hypoxia and angiogenesis. These products generated by dysfunctional peritumoral&#xD;
      adipose tissue create an ideal microenvironment for initiation and tumor progression.&#xD;
&#xD;
      The presence of microbiome in the mesentery of patients with colitis has confirmed the&#xD;
      translocation of microorganisms from the intestine to adjacent tissues, together with the&#xD;
      differences found in the bacterial composition in colonic mucosa and fecal samples between&#xD;
      patients with rectal cancer and healthy individuals, and the prognosis value of the quality&#xD;
      of mesorectum resection suggests that the microbiome present in lymph-fatty tissue in&#xD;
      patients with rectal cancer may be a key element in mesorectum dysfunction, progression and&#xD;
      dissemination of oncological disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of mesorectal microbial biomarkers as prognostic factor for rectal cancer</measure>
    <time_frame>Up to 5 years after rectal cancer surgery</time_frame>
    <description>Correlation between mesorectal microbial signatures and survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mesorectal microbiome evaluation</measure>
    <time_frame>Up to 1 month after rectal cancer surgery</time_frame>
    <description>Qualitative and quantitative analysis of the mesorectal microbiome in patients with rectal cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of mesorectal dysfunctionality and its correlation with microbial dysbiosis</measure>
    <time_frame>Up to 1 month after rectal cancer surgery</time_frame>
    <description>Analysis of mesorectal tissue inflammation, angiogenesis and hypoxia and its correlation with microbial dysbiosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of mesorectal dysfunctionality and dysbiosis on tumor progression</measure>
    <time_frame>Up to 1 month after rectal cancer surgery</time_frame>
    <description>Correlation between mesorectal dysfunction and response to neoadjuvant treatment</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Early-rectal cancer</arm_group_label>
    <description>The patients to be included in this group will be those with Stage I (initial tumor stage). The tumors classified in stage I will be tumors in which the invasion of the submucosa and / or the invasion of the muscularis propria occur. This group will include patients diagnosed preoperatively with tumor stage T1-T2 N0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced-rectal cancer</arm_group_label>
    <description>The patients to be included in this group will be those with Stages II and III, that is, advanced tumors at the time of preoperative diagnosis. Tumors included in this group invade the perirectal fat and / or the surface of the visceral peritoneum and / or invade or adhere to adjacent organs or structures. In addition, any tumor stage with lymph nodes without distant metastases will be included in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synchronous metastasis -rectal cancer</arm_group_label>
    <description>The patients to be included in this group will be those with Stage IV (disseminated tumor stage) in the initial study of the disease. Patients with distant metastases in one organ or more than one organ will be included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stool sample</intervention_name>
    <description>One stool sample will be taken at baseline for microbiota characterization</description>
    <arm_group_label>Advanced-rectal cancer</arm_group_label>
    <arm_group_label>Early-rectal cancer</arm_group_label>
    <arm_group_label>Synchronous metastasis -rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal mucosa sample</intervention_name>
    <description>Characterization of tissue microbiota before and after surgery.</description>
    <arm_group_label>Advanced-rectal cancer</arm_group_label>
    <arm_group_label>Early-rectal cancer</arm_group_label>
    <arm_group_label>Synchronous metastasis -rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mesorectal adipose tissue sample</intervention_name>
    <description>Characterization of tissue microbiota and dysfunction</description>
    <arm_group_label>Advanced-rectal cancer</arm_group_label>
    <arm_group_label>Early-rectal cancer</arm_group_label>
    <arm_group_label>Synchronous metastasis -rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subcutaneous adipose tissue sample</intervention_name>
    <description>Characterization of tissue microbiota and dysfunction</description>
    <arm_group_label>Advanced-rectal cancer</arm_group_label>
    <arm_group_label>Early-rectal cancer</arm_group_label>
    <arm_group_label>Synchronous metastasis -rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Visceral adipose tissue sample</intervention_name>
    <description>Characterization of tissue microbiota and dysfunction</description>
    <arm_group_label>Advanced-rectal cancer</arm_group_label>
    <arm_group_label>Early-rectal cancer</arm_group_label>
    <arm_group_label>Synchronous metastasis -rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary assessment</intervention_name>
    <description>Dietary assessment will be taken at baseline</description>
    <arm_group_label>Advanced-rectal cancer</arm_group_label>
    <arm_group_label>Early-rectal cancer</arm_group_label>
    <arm_group_label>Synchronous metastasis -rectal cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, faeces, rectal mucosa, mesorectal, subcutaneous and visceral adipose tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with rectal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with rectal cancer that will undergo anterior resection for rectal cancer.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histology proven adenocarcinoma or adenoma with or without chemotherapy or neoadjuvant&#xD;
             radiochemotherapy&#xD;
&#xD;
          -  Tumoral stage equal or grater than T1&#xD;
&#xD;
          -  Attempt to R0 resection&#xD;
&#xD;
          -  Signed informed consent by the patient and by the researcher&#xD;
&#xD;
          -  Dietary Questionnaire completed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Colorectal tumor with different histology to adenocarcinoma or adenoma&#xD;
&#xD;
          -  History of colorectal cancer surgery different to the local excision&#xD;
&#xD;
          -  Patients with psychiatric illness, addiction or disorder with inability to understand&#xD;
             informed consent&#xD;
&#xD;
          -  Inability to read or understand any of the languages of the informed consent and&#xD;
             questionnaires (Catalan, spanish)&#xD;
&#xD;
          -  Another synchronous malignancy&#xD;
&#xD;
          -  Emergency Surgery&#xD;
&#xD;
          -  Any patient that medical characteristics present an individual risk raised to be&#xD;
             included and complete the study&#xD;
&#xD;
          -  Severe kidney or liver disease&#xD;
&#xD;
          -  Systemic disease with inflammatory activity, such as rheumatoid arthritis, Crohn's&#xD;
             disease, asthma, chronic infection (HIV,TBC).&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Severe disorder of eating behaviour&#xD;
&#xD;
          -  Clinical symptoms and sings of infection in the previous month&#xD;
&#xD;
          -  Antibiotic, antifungal and antiviral treatment for the last 3 months&#xD;
&#xD;
          -  Anti-inflammatory chronic treatment&#xD;
&#xD;
          -  Major psychiatric antecedents&#xD;
&#xD;
          -  Excessive alcohol intake or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Antoni Codina Cazador, MD, PhD</last_name>
    <phone>+34972940256</phone>
    <email>acodinac.girona.ics@gencat.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Dr. Josep Trueta de Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Codina, MD, PhD</last_name>
      <phone>972940256</phone>
      <email>acodinac.girona.ics@gencat.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Girona Dr.Josep Trueta</investigator_affiliation>
    <investigator_full_name>Antoni Codina Cazador, PhD, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Rectal Neoplasms</keyword>
  <keyword>Colorectal surgery</keyword>
  <keyword>Gastrointestinal Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

